Equillium Inc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All 0FY.MU news ›Equillium, Inc. (NASDAQ:EQ) Stock Has Average Target Price of $7.57 According to Brokerages
Posted by Defense World Staff on Oct 27th, 2026 Read Our Latest Research Report on EQ Equillium (NASDAQ:EQ – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.04) earnings per…
Analysts Are Bullish on These Healthcare Stocks: PolyPid (PYPD), Equillium (EQ)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolyPid (PYPD) and Equillium (EQ) with bullish sentiments. In a report released yesterday, Boobalan Pachaiyappan from Roth MKM reiterated a Buy…
Equillium clears Australian hurdle for first human trial of ulcerative colitis AhR modulator
La Jolla, California-based Equillium (Nasdaq: EQ) has received Australian clearance for a first-in-human trial of EQ504, an oral aryl hydrocarbon receptor (AhR) modulator being developed for ulcerative colitis. Dosing in healthy volunteers…
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation As a potent and selective AhR modulator, EQ504 can affect both immune cell…
Equillium Announces Poster Presentations at the 7th International AHR Conference
LA JOLLA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat... Equillium Announces Poster Presentations at the 7th International AHR Conference LA JOLLA,…
Equillium (NASDAQ: EQ) clears Australia for EQ504 dosing
Posted by Sarita Garza on Oct 8th, 2026 Equillium, Inc. (NASDAQ: EQ) said on October 5, 2026, that it received Australian ethics and regulatory clearance for EQ504's Phase 1 clinical trial. The company expects to begin dosing healthy…
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 ... Equillium Announces Poster Presentation…
Equillium receives HREC clearance for EQ504 in Australia
Equillium (EQ) announced that the company has received Human Research Ethics Committee, or HREC, approval and clearance from the Therapeutic Goo... Equillium receives HREC clearance for EQ504 in Australia Equillium (EQ) announced that the…
Analysts’ Top Healthcare Picks: Equillium (EQ), NeoGenomics (NEO)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Equillium (EQ) and NeoGenomics (NEO) with bullish sentiments. In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy…
Roth MKM Sticks to Its Buy Rating for Equillium (EQ)
Roth MKM analyst Adam Walsh reiterated a Buy rating on Equillium yesterday and set a price target of $12.00. The company’s shares closed yesterday at $1.45. According to TipRanks, Walsh is a 3-star analyst with an average return of 3.8%…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com7
- defenseworld.net1
- themarketsdaily.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.